New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 9, 2014
10:02 EDTSGEN, UMPQ, SLB, SIG, RDS.A, KKR, GOL, CRR, AXP, RTOKY, ITW, E, BRCM, ACMP, MATX, HFC, DB, AINVOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Access Midstream (ACMP) upgraded to Buy from Neutral at Ladenburg... American Express (AXP) upgraded at Guggenheim... Apollo Investment (AINV) upgraded to Buy from Neutral at SunTrust... Broadcom (BRCM) upgraded to Outperform from Perform at Oppenheimer... CARBO Ceramics (CRR) upgraded to Neutral from Sell at Guggenheim... Deutsche Bank (DB) upgraded to Overweight from Neutral at JPMorgan... Eni SpA (E) upgraded to Buy from Hold at Deutsche Bank... GOL Linhas (GOL) upgraded to Outperform from Market Perform at Raymond James... HollyFrontier (HFC) upgraded to Outperform at Wells Fargo... Illinois Tool Works (ITW) upgraded to Buy from Hold at Argus... KKR (KKR) upgraded to Outperform from Neutral at Credit Suisse... Matson (MATX) upgraded to Buy from Hold at BB&T... Rentokil (RTOKY) upgraded to Outperform from Neutral at Credit Suisse... Royal Dutch Shell (RDS.A) upgraded to Buy from Hold at Deutsche Bank... Schlumberger (SLB) upgraded to Overweight from Neutral at HSBC... Seattle Genetics (SGEN) upgraded to Buy from Neutral at UBS... Signet Jewelers (SIG) resumed with an Overweight from Neutral at JPMorgan... Umpqua Holdings (UMPQ) upgraded to Equal Weight from Underweight at Barclays.
News For A;SLB;SGEN;SIG;UMPQ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
10:35 EDTAOptions with increasing implied volatility
Options with increasing implied volatility: ARCP RCAP GREK RSX A
10:17 EDTUMPQOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:13 EDTUMPQUmpqua Holdings initiated with a Market Perform at Wells Fargo
Subscribe for More Information
December 18, 2014
11:08 EDTAOptions with increasing implied volatility
Options with increasing implied volatility: CZR RSX HLF YPF ARCP MGM A MCD
09:03 EDTSGENSeattle Genetics initiates Phase 1b trial of SGN-CD33A
Seattle Genetics announced initiation of a phase 1b clinical trial of SGN-CD33A in combination with standard of care chemotherapy, including cytarabine and daunorubicin, for patients with newly diagnosed acute myeloid leukemia. The trial will also evaluate SGN-CD33A in the consolidation setting for AML, both in combination with cytarabine and as a single-agent maintenance regimen. SGN-CD33A is a novel antibody-drug conjugate targeted to CD33 utilizing Seattle Genetics’ newest technology. CD33 is expressed on most AML cells regardless of subtype, cytogenetic abnormality or underlying mutational heterogeneity. SGN-CD33A is also under evaluation in an ongoing phase 1 dose escalation trial as a single-agent or in combination with hypomethylating agents for the treatment of patients who have relapsed AML or have declined intensive frontline therapy. The study is a phase 1b, open-label, multi-center, dose-escalation clinical trial designed to evaluate SGN-CD33A administered in combination with frontline standard of care regimens for induction (cytarabine and daunorubicin) and/or consolidation. In addition, the study will evaluate single-agent SGN-CD33A as a maintenance regimen. The primary endpoints are determination of the maximum tolerated dose and safety profile of SGN-CD33A in these settings. In addition, the trial will evaluate anti-leukemic activity, pharmacokinetics, progression-free survival and overall survival. The phase 1b trial will enroll approximately 90 patients at multiple centers in the United States.
December 17, 2014
12:51 EDTSLBNY state to ban fracking next year, CNBC reports
Publicly traded companies in the oil services space include Baker Hughes (BHI), Diamond Offshore (DO), Halliburton (HAL), Nabors Industries (NBR), Noble Corp. (NE), Rowan Companies (RDC), Schlumberger (SLB), Transocean (RIG) and Weatherford (WFT).
December 9, 2014
10:23 EDTSLBOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:50 EDTSLBSchlumberger downgraded to Hold from Buy at Jefferies
Subscribe for More Information
December 8, 2014
19:42 EDTSGENSeattle Genetics says Adcetris 'demonstrates antitumor activity'
Seattle Genetics highlighted two separate Adcetris data presentations in relapsed/refractory and frontline diffuse large B-cell lymphoma, or DLBCL, at the 56th American Society of Hematology, or ASH, Annual Meeting and Exposition. Adcetris is an antibody-drug conjugate directed to CD30, which is expressed in classical Hodgkin lymphoma, anaplastic large cell lymphoma and several other types of non-Hodgkin lymphoma. Seattle Genetics CEO Clay Siegall said, “The updated phase 2 data at ASH demonstrate encouraging activity of Adcetris in relapsed/refractory DLBCL, even when CD30 is undetectable by standard immunohistochemistry methods. In addition, our data show that Adcetris can be safely combined with RCHOP in the frontline setting with a strong complete remission rate in high-intermediate and high-risk patients. The activity observed supports our plans to initiate a randomized phase 2 clinical trial of Adcetris for relapsed CD30-positive DLBCL patients during 2015 and to pursue possible frontline DLBCL combination trials."
19:41 EDTSGENSeattle Genetics says planning phase 1b combination trial for SGN-CD33A
Subscribe for More Information
10:11 EDTSIGHigh option volume stocks
Subscribe for More Information
10:04 EDTSGENSeattle Genetics highlights 'encouraging' long-term outcomes in Phase 1 trial
Seattle Genetics highlighted multiple ADCETRIS data presentations in frontline and salvage Hodgkin lymphoma at the 56th American Society of Hematology Annual Meeting and Exposition taking place in San Francisco, CA, December 6-9. ADCETRIS is an antibody-drug conjugate directed to CD30, which is expressed in classical HL and systemic anaplastic large cell lymphoma, a type of T-cell lymphoma. Data highlighted in oral sessions include encouraging long-term outcomes from a phase 1 trial evaluating ADCETRIS in combination with AVD chemotherapy in frontline HL, as well as strong activity evaluating ADCETRIS combination therapy in second-line HL and ADCETRIS monotherapy or combination therapy in frontline HL patients age 60 and older. In addition, encouraging data from multiple investigator-sponsored trials were featured in oral and poster sessions evaluating ADCETRIS in frontline and salvage HL and in non-Hodgkin lymphoma settings.
08:33 EDTSGENSeattle Genetics should be bought on weakness, says RBC Capital
RBC Capital believes that Seattle Genetics' shares could be under pressure today due to questions around its AETHERA data and the checkpoint inhibitor efficacy of its ADCETRIS drug. However, the firm says that other issues are more important over the longer term, including the efficacy of ADCs as a cancer treatment, the emergence of other pipeline products and therapeutic approaches, and efficient development pathways to the market. The firm keeps a $48 price target and Outperform rating on Seattle Genetics.
December 7, 2014
13:23 EDTSGENSeattle Genetics, Takeda announce four-year data from ADCETRIS trial
Subscribe for More Information
12:50 EDTSGENSeattle Genetics presents data from SGN-CD19A antibody-drug conjugate
Subscribe for More Information
12:44 EDTSGENSeattle Genetics, Takeda report Phase 3 AETHERA trial data from Adcetris
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use